Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks
|
|
- Laureen Johnson
- 6 years ago
- Views:
Transcription
1 Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks
2 Biosafety testing within the manufacturing process should be established in the early stages of drug development. We offer biosafety testing services throughout development and manufacture: ` ` Master Cell Bank (MCB) ` ` Working Cell Bank (WCB) ` ` End of Production Cell Bank (EPC) `Bulk ` Harvest ` ` Genetic Stability of Cell Banks ` ` Final Product and GMP Lot Release All of our biosafety testing is compliant with appropriate GMP, GLP and GCP quality standards. Further information on our range of services is available on our website: Introduction To Safety Testing For CHO Cell Banks CHO cells are by far the most commonly used production cell lines in the biopharmaceutical industry. These cells are used for a number of reasons including the good safety record of no known incidence of patient infection from a contaminant in a product manufactured on these cells. The guidelines for the safety testing of these products were globally harmonized in 2003 to allow a world-wide single panel of tests to assist drug developers to move through regulatory submissions. Since 2007, BioOutsource has performed biosafety testing of over 200 recombinant protein products from Chinese Hamster Ovary (CHO) cell banks. The general testing strategy outlined in this document complies with international regulatory guidelines and remains current owing to our on-going dialogue with worldwide regulatory authorities. 1 The guidelines outline a safety testing programme which is dependent on three aspects; testing of the starting materials which includes the cell banks, testing of the in-process materials which are typically the bulk harvest and the ultimate stage which is validation of the virus removal ability of the downstream purification process. The full profile of safety testing is developed over a number of years as the clinical trials are engaged and the product moves to commercialisation. BioOutsource scientists have a wealth of experience and knowledge and will advise on the most appropriate and cost-effective testing strategy to meet scientific and regulatory requirements. The package of testing recommended by our scientists take into consideration the history of the cell line, raw materials used during production, product dosage, therapeutic application, clinical stage, patient population, in addition to other factors which may impact the strategy. A general overview of testing requirements is described in this document. From the International Congress on Harmonisation in 2003 each regulatory jurisdiction prepared its own safety testing guideline which all have slightly different wording. Therefore the guidance for testing cell banks is described in European Medicines Agency and the United States Food and Drug Administration Guidance documents. Our scientists have devised a package of recommended safety testing and characterisation for CHO projects to ensure the ultimate safety of the final product which will satisfy both agencies. A general overview of tests required during production of a recombinant product is detailed below. Test MCB WCB EPC Bulk Harvest Drug Substance Contents Introduction to Safety Testing for CHO Cell Banks 3 Table 1 General Testing in Compliance with ICH Q5A 3 Master and End Of Production Cell Bank Testing 3 Table 2 MCB and EPC Testing 4 Working Cell Bank (WCB) Testing 5 Table 3 WCB Testing 5 Bulk Harvest (Unprocessed Bulk) Testing 5 Table 4 Unprocessed Bulk Harvest Testing 5 Purified Bulk Harvest and Final Product Testing 5 Table 5 Purified Bulk Harvest and Final Product Testing 6 Genetic Stability Testing 6 Identity Mycoplasma Sterility In vitro assays In vivo assays Antibody tests Retrovirus infectivity Reverse transcriptase Electron microscopy Species specific tests Residual DNA Table 1 General testing requirement in compliance with ICH Q5A Table 6 Genetic Stability Testing 6 Additional Testing 6 2 3
3 Master and End of Production Cell Bank Testing Cells used in the production of biologic products are initially banked as a Master Cell Bank (MCB), which consists of a bank of fully characterized cells processed together to ensure uniformity and stability. Characterisation and testing of the MCB for bacterial and viral contaminants should be performed as described in International Conference on Harmonisation (ICH) Q5A prior to initiation of a Phase I clinical trial 1. In addition to testing for the presence of microbiological contaminants, extensive screening for the presence of both exogenous and endogenous viral contamination should be performed. Description Sterility test and qualification of sterility test by direct inoculation (Eu Pharm current edition sterility, US Pharmacopoeia <71>) (Technical Note T1) Test for mycoplasma including mycoplasmastasis assay (EP and USP <63> ) (Agar, broth and indicator cells) (Technical Note T1) Appearance SP-GSM Test 1% of cell bank (minimum 2 vials) plus 1.5x number tested for qualification SP-GSM vial, sufficient for test and stasis Morphology by light microscopy TSOP179 1 Live cells required Identity Random amplified polymorphic DNA barcoding assay for cell line identity (Technical Note T2) Adventitious Agents 28 day in vitro assay using 3 detector cell lines (Technical Note T3) TSOP182 6 In vivo adventitious agent assay: adult and suckling mice and embryonated eggs as outlined in ICH Q5A (Technical Note T4) Retroviruses (Technical Note T5) Detection of murine xenotropic retroviruses by Mus dunni co-cultivation followed by MiCl S+L- assay TSOP vial containing minimum 1e6 cells Minimum 1e7 cells (plus 20 ml supernatant per detector cell line = 60 ml supernatant) SP-GSM ml at 1e7 cells /ml TSOP131 6 Live cells required Fluorescent Product Enhanced Reverse Transcriptase TSOP ml cell free supernatant Examination of 200 cell profiles by Transmission Electron Microscopy (TEM) TSOP190 8 Live cells required Species Specific Viruses MCB testing is performed once and the testing package is repeated on the End of Production Cell Bank (EPC) in order to determine that the cells remain unchanged from the original cells, and to detect any low level contamination which may have been present but undetected in the MCB. Testing the EPC also allows detection of latent infections as well as any contaminants which may have introduced during the production process. Testing of EPC used in production should be performed prior to submitting a Product Licence Application (PLA). A summary of the testing required for for MCB and EoPCB is described in Table 2. Please note the sample volumes listed in the tables below are a guide and may vary for specific projects. Please speak to our scientists, who can advise on the required sample volumes for each project. Hamster Antibody Production Test (HAP), 5 viruses (Technical Note T6) On request 12 1e7 cells/ml in 2 x 5 ml spent supernatant Mouse Antibody Production Test (MAP), 16 viruses (Technical Note T7) On request 12 1e7 cells/ml in 2 x 5 ml spent supernatant Bovine and Porcine virus screen by real-time PCR (Technical Note T8) TSOP vial containing minimum 5e6 cells Detection of MVM by real-time PCR (Technical Note T9) TSOP vial containing minimum 1e6 cells Detection of Vesivirus by real-time PCR (Technical Note T9) TSOP vial containing minimum 1e6 cells Working Cell Bank (WCB) Testing The WCB is derived from a vial of the MCB, and may be used as a starting cell substrate for drug production. Less extensive testing is required for the WCB, as the MCB has already been fully characterized, hence a package of limited testing should be performed to confirm identity, ensure that the bank is sterile and demonstrate absence of mycoplasma. In some cases full testing may be performed on the WCB as an alternative to the MCB. An outline of testing required on the WCB is shown in Table 3. Description Sterility test by direct inoculation (Eu Pharm current edition sterility, US Pharmacopeia <71> (Technical Note T1) SP-GSM Test 1% of cell bank (minimum 2 vials) Test for mycoplasma (Eu Pharm, current edition mycoplasmas and USP - NF Mycoplasma test, USP <63> current edition) (Technical Note T1) SP-GSM Test 1 vial + 23 ml supernatant Identity Random amplified polymorphic DNA barcoding assay for cell line identity (Technical Note T2) Table 3 WCB testing Bulk Harvest (Unprocessed Bulk) Testing TSOP vial containing minimum 1e6 cells A representative of the unprocessed bulk, which consists of pooled harvests of cells and culture media from the fermenter or production reactor, should be analysed for the presence of virus. Data from at least 3 lots of bulk harvest is required for submission to the regulatory authorities. Certain specifics relating to the process, materials and intended product may need to be taken into consideration when determining the bulk harvest testing schedule, however, in general, the following testing regime would be recommended. Description Microbiological examination of non-sterile products: microbial enumeration test (Eu Pharm current edition ) (Bioburden) Test for Mycoplasma including mycoplasmastasis (Eu Pharm, Current edition mycoplasmas and USP - NF Mycoplasma test, USP <63> current edition ) (Technical Note T1) Adventitious Agents SP-GSM ml SP-GSM ml 14 day in vitro assay using 3 detector cell lines (EP and FDA compliant) TSOP138 3 In vivo adventitious agent assay: adult and suckling mice and embryonated eggs as outlined in ICH Q5A Retroviruses Up to maximum of 20 ml per detector cell line SP-GSM ml at 1e7 cells /ml Virus detection and quantitation by thin section TEM TSOP ml Species Specific Viruses Detection of MVM by real-time PCR TSOP ml Table 4 Unprocessed Bulk Harvest Testing Genetic Analysis Confirmation of sequence of transgene (coding region) by mrna sequencing Design and qualification of a real-time PCR for copy number determination of the transgene TSOP vial containing minimum 1e6 cells TSOP Purified Bulk Drug Substance and Final Product Testing The purified bulk drug substance is a sample taken at the end of the production process after downstream purification activities have been performed. These samples are not usually analysed for the presence of virus if the host cell line has been tested and found to be negative, and, the unprocessed bulk testing has been shown to be negative. Determination of insert gene copy number by quantitative real time PCR TSOP vial containing minimum 1e6 cells Restriction enzyme analysis by Southern Blot TSOP vial containing minimum 5e6 cells Table 2 MCB and EPC testing Depending on the manufacturing process these may be individual samples or pooled samples from different unprocessed bulk harvests. While certain specifics in relation to the process, materials, and intended product may need to be taken into further consideration with the testing schedule, in general, the following testing regime is recommended. 4 5
4 Description Technical Notes T1. Qualification of the cell bank sample in the mycoplasma and sterility tests is required once on the MCB and first batch of Bulk Harvest and does not need to be repeated on future samples unless there is a change in the materials or manufacturing method. For the sterility test, if antibiotics have been used in cell culture, an alternative membrane filtration sterility test can be performed. Genetic Stability and Identity Testing ICH Guidelines indicate that the stability and integrity of the insertion sequence needs to be characterized to ensure stable production of the correct protein. There are a number of steps which are required to be undertaken to ensure the cell line and production system is acceptable. The minimal characterisation required is to assess the MCB and the EPC. Testing can also be carried out at other times but is particularly useful where there are changes to the fermentation process. BioOutsource offers the following genetic stability assays and can advise on the most appropriate approach for your product. Description Confirmation of sequence of transgene (coding region) by mrna sequencing TSOP vial containing minimum 1e6 cells Random amplified polymorphic DNA (RAPD) analysis TSOP vial containing minimum 1e6 cells DNA barcoding assay for cell identity (Technical Note T2) TSOP vial containing minimum 1e6 cells Determination of insert gene copy number by quantitative real time PCR TSOP vial containing minimum 1e6 cells Restriction enzyme analysis by Southern Blot TSOP vial containing minimum 5e6 cells Table 6 Genetic Stability Testing Additional Testing Qualification and Validation of s `` Microbiological examination of non-sterile products: microbial enumeration test EU Pharm current edition Bioburden Sterility test and qualification of sterility test by direct inoculation EU Pharm current edition Sterility and US Pharmacopeia <71> Endotoxin BioOutsource has extensive experience in the qualification and validation on all assays used to support safety testing of a licensed product. BioOutsource Certification SP-GSM SP-GSM Detection of Endotoxin using chromogenic LAL Kit TSOP201 1 General Safety/Abnormal Toxicity Abnormal Toxicity test EU Pharm current edition SP-GSM Residual Impurities (Bulk Drug Substance only) Detection of residual CHO DNA by real time PCR TSOP ml Determination of CHO Host Cell Proteins (HCP) by ELISA assay (Technical Note T10) Table 5 Purified Bulk Harvest and Final Product Testing TSOP ml 10mL Bulk drug substance Final product, as per parenteral guidelines, dependant on batch size 1 ml of Drug Substance 1 ml of Final Product No more than 7 human does of final product BioOutsource has both GMP and GLP certification; last inspection dates being 27th and 28th July and 16th September 2015 respectively. Following several successful MHRA inspections, we were rated with a low risk rating and have continued GMP and GLP compliance and certification; valid until We were also successfully audited by the U.S. Food and Drug Administration on 25th and 26th January The inspection confirmed that our Glasgow site, is compliant with the principles and guidelines of GMP. Furthermore, not a single 483 observation for non-compliance was issued. T2. Isoenzyme analysis of cell lines is no longer available, due to supply issues. DNA barcoding assay is available as an alternative to isoenzyme analysis of cell lines. T3. For the MCB, the more sensitive 28 day in vitro assay is recommended. T4. For in vivo tests, various options for inoculation include both the yolk sac and allantoic membrane in eggs, suckling mice, intracranial and intramuscular route in adult mice, as well as the option to include guinea pigs. Animal Volume Required Concentration Yolk sac 6 ml 1 x 10 7 cells/ml Allantoic 6 ml 1 x 10 7 cells/ml Suckling Mice 2 ml 1 x 10 7 cells/ml Adult Mice Intracranial route 1 ml 1 x 10 7 cells/ml Intramuscular route 2 ml 1 x 10 7 cells/ml Guinea Pigs 26 ml 4 x 10 5 cells/ml T5. CHO cell lines contain an endogenous, defective, noninfectious retrovirus. When testing for retrovirus, a number of approaches can be taken and it is not necessary to perform all of the procedures. a. The electron microscope is a powerful tool used to visualize retroviral particles (for example budding C-type, R-type and intracisternal A-type particles) b. The PERT assay is used to detect enzymatic activity (which could provide a positive result as hamster cells contain an endogenous, defective, non-infectious retrovirus). c. Cell based infectivity assays for detection will determine if virus detected is infectious. In the event that infectious virus is detected, cells can be co-cultivated with a human cell line to determine if infection of human cells is possible. The PERT test may produce a positive result, and should only be performed following the infectivity and TEM tests. T6. The HAP test will detect the following viruses; Lymphocytic Choriomeningitis virus (LCMV), Pneumonia Virus of Mice (PVM), Reovirus Type 3, Sendai Virus and Simian virus type 5 (SV5). T7. The MAP test will detect the following viruses; Ectromelia Virus; Lymphocytic Choriomeningitis virus, Hantaan Virus, Pneumonia Virus of Mice (PVM), Reovirus Type 3, Mouse Theilers Encephalomyelitis Virus, Lactic Dehydrogenase Virus, Sendai Virus, Minute Virus of Mice (MVM), Mouse Adenovirus, Mouse Cytomegalovirus, Mouse Hepatitis Virus, Mouse Rotavirus, Polyoma Virus, Thymic Virus and K virus. T8. If at any point during production, cells have come into contact with bovine serum or porcine trypsin full testing for a range of bovine and porcine viruses should be performed. Bovine Polyomavirus, in particular, has been requested by the European regulators, as it has been found as a frequent contaminant of foetal bovine serum. T9. It is recommended that testing for the presence of Minute Virus of Mice (MVM) should be performed on production harvests and the EPC. This virus has previously been detected as a contaminant in CHO fermentations, and testing for its presence can be performed by inclusion of an additional cell line susceptible to MVM infection in the in vitro assay, for example 324K cells, or alternatively by performing a real time PCR assay. Similarly vesivirus has also been detected in biological materials used in product manufacture. T10. A validated HCP assay is required for the final product testing of licenced biologics. The assay listed here is a screening assay for early phase clinical material. Further discussion will be required if BioOutsource is to develop a specific HCP assay for late phase material. Please contact us for further information regarding this. s 1. ICH Q5A (R1) Viral Safety Evaluation of Biotechnology products derived from cell lines of human or animal origin. 6 7
5 Sartorius Stedim BioOutsource Global Facilities For further contacts, visit Glasgow, UK Cambridge, USA Pangyo, South Korea Glasgow 1 Technology Terrace, Todd Campus, West of Scotland Science Park, Glasgow, G20 0XA, United Kingdom Phone Fax Cambridge 245 First St, Cambridge, Boston, MA 02142, United States Phone Follow Us Pangyo 8th Floor, Solid Space B/D, PanGyoYeok-Ro 220, BunDang-Gu SeongNam-Si, GyeongGi-Do, South Korea Phone Fax Specifications subject to change without notice. Printed in the EU on paper bleached without chlorine. Publication No.: S e Order No.: Ver
Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks
Safety Testing of Chinese Hamster Ovary (CHO) Cell Banks About Sartorius Stedim BioOutsource Sartorius Stedim BioOutsource Ltd. is a leading provider of contract testing services to the global biopharmaceutical
More informationCell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products
Cell Line Characterization and Product Testing for CHO-Derived Biopharmaceutical Products Founded in 96, Eurofins Lancaster Laboratories is a global leader in comprehensive laboratory services enabling
More informationBiosafety Considerations for Cell Based Viral Vaccines. Margaret Temple SGS Vitrology Site Director Glasgow - UK
Biosafety Considerations for Cell Based Viral Vaccines Margaret Temple SGS Vitrology Site Director Glasgow - UK Presentation Outline: Sources of adventitious contamination in biological material Safety
More informationOverview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
More informationEuropean Guideline for Virus Safety Evaluation of Clinical Trial Material
Plasma Product Biotechnology Meeting, May 8 12, 2007 European Guideline for Virus Safety Evaluation of Clinical Trial Material Dr. Hannelore Willkommen Vice President Regulatory Affairs, NewLab Bioquality
More informationEuropean Medicines Agency
European Medicines Agency October 1997 CPMP/ICH/295/95 ICH Topic Q 5 A (R1) Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal
More informationCritical Quality Attributes for Live Viral Vaccines. Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA
Critical Quality Attributes for Live Viral Vaccines Mark S. Galinski Vaccine Analytical Sciences, MedImmune, Mountain View, CA USA Terminology Quality Release Standards The specifications and procedures
More informationFast decisions instead of delays Quality Control through outstanding design
Fast decisions instead of delays Quality Control through outstanding design We are CustomBiotech from Roche In your operations, behind your decisions, powering your products You are driving a paradigm
More informationThe Elite Provider. Cell & Gene. Therapy Manufacturing
The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationGuidance for FDA Review Staff and Sponsors
Guidance for FDA Review Staff and Sponsors Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) DRAFT GUIDANCE
More informationOutsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D.
Outsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D. Should You Partner Manufacturing? $$$ versus Control 2 Ph. 1 Registration Trials Commercial Launch CMO CMO or Partner CMO
More informationAnnex 4. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology
Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology Replacement of Annex 3 of WHO Technical Report Series, No. 814 Introduction 177
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationSmall Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre
Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre Keith Williams Business Development Manager - Clinical Biotechnology Centre CBC - Aims and Objectives
More informationProduct Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex
Product Permission Document (PPD) of Botulinum Toxin Type A for Injection Ph.Eur Purified Neurotoxin Complex Brand Name : BOTO GENIE 1. Introduction : BOTO GENIE (Botulinum Toxin Type A for Injection Ph.Eur)
More informationGuidance for Industry
Guidance for Industry Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More informationReference Materials for Adeno-Associated Viruses
Reference Materials for Adeno-Associated Viruses : Recommendations of the Quality Control Sub-Committee John Chiorini (NIH-NIDCR) Paul Husak (Cell Genesys) Gabrielle Kroener-Lux (Progen) James Marich (Cell
More informationNational Institute of Immunology, New Delhi
National Institute of Immunology, New Delhi QUOTATION INVITATION NOTICE For Website Ref: NII/AKS/GPL/2013 Date: 25/12/2013 Quotations are invited from technical firms specializing in either both or one
More informationSupplies and Reagents
Supplies and Reagents PACT Workshop: Design & Operation of GMP Cell Therapy Facilities April 4 th /5 th, 2006 NHLBI-sponsored PACT Group Guidance for Industry INDs Approaches to Complying with CGMP During
More informationCQAs for C> Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline
CQAs for C> Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development
More informationSubject Index. chromatography step, 125-
A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade
More informationRegulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products
Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT
More informationGuideline on quality of biological active substances produced by transgene expression in animals
1 2 3 24 May 2012 EMA/CHMP/BWP/159188/2012 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on quality of biological active substances produced by transgene expression Draft Draft
More informationRegulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank
Regulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank Rashmi Rawat, Ph.D. Office of Biotechnology Products OPQ/CDER/FDA Informa Life Sciences Annual Cell Line Development
More informationMONOCLONAL ANTIBODIES AND BIOSIMILARS production, naming, pharmacovigilance and other pharmaceutical quality aspects
1 MONOCLONAL ANTIBODIES AND BIOSIMILARS production, naming, pharmacovigilance and other pharmaceutical quality aspects Prof. dr. Jos G.W. Kosterink Department of Clinical Pharmacy and Pharmacology University
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationGala s Gene Product Expression (GPEx ) Platform
Gala Biotech A Company with Gene Insertion and Manufacturing Technologies for the Next Generation of Gene Expression and Biologics Production Gala s Gene Product Expression (GPEx ) Platform Rapid creation
More informationViral Clearance Services. Unsurpassed experience, science and compliance
Viral Clearance Services Unsurpassed experience, science and compliance What We Do BioReliance has conducted thousands of Clearance studies for clients around the globe. These studies are required by regulatory
More informationAccredited Laboratory
Accredited Laboratory A2LA has accredited St. Paul, MN for technical competence in the field of Biological Testing This laboratory is accredited in accordance with the recognized International Standard
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES
More informationHow can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines?
How can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines? Marion F. Gruber, Ph.D. Office of Vaccines Research and Review CBER/FDA Global Vaccine
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationDownscaling Purification Processes for Biologics
Clearance Services Considerations in Downscaling Purification Processes for Biologics O-0280608 About BioReliance BioReliance Corporation is a leading provider of cost-effective contract services to the
More informationManufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective
Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of
More informationApplication of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
More informationEuropean Directorate for the Quality of Medicines & HealthCare (EDQM)
European Directorate for the Quality of Medicines & HealthCare (EDQM) INTERNATIONAL REGULATORY FORUM OF HUMAN CELL THERAPY AND GENE THERAPY PRODUCTS 16 MARCH 2016, OSAKA, JAPAN Dr Stephen J. Wicks Scientific
More informationGuidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE
Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationEuropean Regulatory Experiences and Expectations of HCP Analysis and Control
HCP Strategy Forum, Washington DC, January 26, 2015 www.pei.de European Regulatory Experiences and Expectations of HCP Analysis and Control Blood Products: Dr. Erika Friedl, PEI (DE) Discalimer: The views
More informationJ. Fraser Wright, Ph.D.
Towards Better Characterization of Recombinant AAV Gene Transfer Vectors: Case Studies Illustrating Challenges with Dose Determining Vector Concentration methods J. Fraser Wright, Ph.D. Well Characterized
More informationA.1 Contents file 4 to 5 A.1 (1)
Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW
More informationManufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
More informationTechnical Report No. 71 Emerging Methods for Virus Detection
Technical Report No. 71 Emerging Methods for Virus Detection PDA Emerging Methods for Virus Detection Technical Report Team Authors Arifa S. Khan, Ph.D., U.S. FDA/CBER, Co-Leader Kathryn E. King, Ph.D.,
More informationJapanese Application Form: PMDA s Perspective on Manufacturing Process Description
Japanese Application Form: PMDA s Perspective on Manufacturing Process Description Reiko YANAGIHARA, Ph.D. Principal Reviewer Division of Pharmacopoeia and Standards for Drugs Office of Standards and Guideline
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationQuestions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility
15 June 2017 EMA/CVMP/ADVENT/751229/2016 Committee for Medicinal Products for Veterinary Use (CVMP) Questions and Answers on allogenic stem cell-based products for veterinary use: Draft problem statement
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE GUIDELINES INDEX BATCH Q: Quality Q1A(R2) Stability Testing of New Drug Substances
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 Guidelines on procedures and data requirements for changes to approved biotherapeutic products World Health Organization
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationExcipient Albumin CSL Behring Human Serum Albumin
Excipient Albumin CSL Behring Human Serum Albumin For more information, contact CSL Behring USA: (610) 878-4000 1020 First Avenue King of Prussia, PA 19406-0901 Switzerland: +41 31 344 44 44 Wandorfstrasse
More informationA Regulatory Perspective on Characterization and Control of Process-Related Impurities
A Regulatory Perspective on Characterization and Control of Process-Related Impurities Christopher Downey, PhD FDA/CDER Office of Biotechnology Products CASSS Bay Area Discussion Group June 2017 Disclaimer
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationGuideline on requirements for the production and control of immunological veterinary medicinal products
14 June 2012 EMA/CVMP/IWP/206555/2010 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on requirements for the production and control of immunological veterinary Draft agreed by Immunologicals
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products. Proposed guidelines
0 0 0 0 WHO/PAC for BTPs_DRAFT/ Oct 0 ENGLISH ONLY Guidelines on procedures and data requirements for changes to approved biotherapeutic products Proposed guidelines NOTE: This document has been prepared
More informationRapid Microbiological Methods Understanding the Technologies and Regulatory Expectations for Validation and Implementation
Rapid Microbiological Methods Understanding the Technologies and Regulatory Expectations for Validation and Implementation Michael J. Miller, Ph.D. President Microbiology: Where We ve Been 1683. Anton
More informationCase Study: Examples Relating to the Quality Control of Cell-based Products
Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association
More informationPreclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015
Preclinical Development Drugs Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Product Development: Development process: File Approval Drug Discovery Preclinical Phase 1 Phase 2 Phase 3 Lifecycle
More informationRegulatory Implications for Global Manufacturing Development of Regenerative Medicines
Regulatory Implications for Global Manufacturing Development of Regenerative Medicines Katherine Tsokas, JD June 2017 Global Regulatory Affairs Janssen Research & Development, LLC Jessica Riley, Shells
More informationQualified Persons in the Pharmaceutical Industry Study Guide
Qualified Persons in the Pharmaceutical Industry Study Guide Guide to the knowledge and practical experience required by Qualified Persons relating to pharmaceutical manufacturing in the UK February 2013
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationFRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS Close-up of large scale UF/DF control unit conditions and
More informationSubmission of comments on the Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014)
31 August 2015 Submission of comments on the Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products' (EMA/CAT/80183/2014) Comments from: Name of organisation or
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationViraBind PLUS Retrovirus Concentration and Purification Kit
Product Manual ViraBind PLUS Retrovirus Concentration and Purification Kit Catalog Number VPK-135 2 preps FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Retroviral gene transfer
More informationTurboFect in vitro Transfection Reagent. Description. Storage. Reagents to be Supplied by the User. #R ml ( for in vitro transfections)
TurboFect in vitro Transfection Reagent #R0531 1 ml ( for 300-500 in vitro transfections) Description TurboFect in vitro Transfection Reagent* is a sterile solution of a cationic polymer in water. The
More informationRecombinant DNA Technology. The Role of Recombinant DNA Technology in Biotechnology. yeast. Biotechnology. Recombinant DNA technology.
PowerPoint Lecture Presentations prepared by Mindy Miller-Kittrell, North Carolina State University C H A P T E R 8 Recombinant DNA Technology The Role of Recombinant DNA Technology in Biotechnology Biotechnology?
More informationArchived Content. This content was archived on June 24, 2013.
This content was archived on June 24, 2013. Archived Content Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationParadigm Change in Manufacturing Operations
Technical Report No. 54-4 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 3: Case Studies in the Manufacturing of Biotechnological Bulk Drug
More informationUSP Standards for Ancillary Materials
Quality Standards for Medicines, Supplements, and Food Ingredients throughout the World USP Standards for Ancillary Materials 8 th Annual Somatic Cell Therapy Symposium September 22-24 2008 Fouad Atouf,
More informationICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada
ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada Anthony Ridgway, Ph.D. Senior Regulatory Scientist Biologics & Genetic Therapies Directorate Health Canada Open
More informationContent of the dossier for chemical purity and microbiological quality
Division Certification of Substances CP/CB PUBLIC DOCUMENT (Level 1) English only/anglais seulement PA/PH/ CEP (0) 1 R February 0 Certification of suitability of Monographs of the European Pharmacopoeia
More informationViraBind PLUS Retrovirus Concentration and Purification Mega Kit
Product Manual ViraBind PLUS Retrovirus Concentration and Purification Mega Kit Catalog Number VPK-136 VPK-136-5 2 preps 10 preps FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction
More informationChapter 9 Genetic Engineering
Chapter 9 Genetic Engineering Biotechnology: use of microbes to make a protein product Recombinant DNA Technology: Insertion or modification of genes to produce desired proteins Genetic engineering: manipulation
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
Ref. Ares(2012)778531-28/06/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health Systems and Products Medicinal Products - Quality, safety and efficacy Brussels, SANCO/AM/sl/ddg1.d.6(2012)860362
More information[DOCKET NO. 96N-0400] Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications
[DOCKET NO. 96N-0400] Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications For further information about this document, contact: Valerie A. Butler Center for Biologics
More informationProcess validation is defined in the
Process Validation How Much to Do and When to Do It Anurag S. Rathore, Joseph F. Noferi, Edward R. Arling, Gail Sofer, Peter Watler, and Rhona O Leary The trick to process validation, these industry experts
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationComparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm
Comparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm Jarrod Dean Principal Research Associate, Analytical Development Sanofi Presented by GTC, a
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More information4/26/2015. Cut DNA either: Cut DNA either:
Ch.20 Enzymes that cut DNA at specific sequences (restriction sites) resulting in segments of DNA (restriction fragments) Typically 4-8 bp in length & often palindromic Isolated from bacteria (Hundreds
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationGeneCellin TM Transfection Reagent Protocol
GeneCellin TM Transfection Reagent Protocol Table of content Description......3 Content......3 Storage......3 Certificate of quality......4 Parameters influencing transfection efficiency......4 Nucleic
More informationCell History File Explanatory Introduction
CELL HISTORY FILE TEMPLATE Cell History File Explanatory Introduction This template Cell History File (CHF) is a non-mandatory template document intended for establishments and companies involved in the
More informationVaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study.
Vaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study. CMC Forum Vienna May 25-27 Vaccine workshop M.-C. Uwamwezi, Senior scientist Regulatory Affairs,
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationCHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON THE QUALITY OF BIOLOGICAL ACTIVE SUBSTANCES PRODUCED BY STABLE TRANSGENE EXPRESSION IN HIGHER PLANTS
European Medicines Agency Evaluation of Medicines for Human Use London, 24 July 2008 Doc. Ref. EMEA/CHMP/BWP/48316/2006 CHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON THE QUALITY OF BIOLOGICAL ACTIVE SUBSTANCES
More informationIntroducing new DNA into the genome requires cloning the donor sequence, delivery of the cloned DNA into the cell, and integration into the genome.
Key Terms Chapter 32: Genetic Engineering Cloning describes propagation of a DNA sequence by incorporating it into a hybrid construct that can be replicated in a host cell. A cloning vector is a plasmid
More informationOptimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk. Feng Gao, MD, PhD. AutekBio CO.
Optimization Strategies of Expression Cell Line Construction to Reduce the Biological Drug Development Risk Feng Gao, MD, PhD AutekBio CO. Expression Systems used for Approved Antibody and Antibody-Related
More informationTom Sulpizio and Jeff Taniguchi, Advanced Minerals Corporation A Member of Imerys 130 Castilian Way, Santa Barbara, CA 93117
ADVANCES IN DISPOSABLE DIATOMITE FILTER AID SYSTEMS FOR CGMP BIOSEPARATIONS Session Pretreatment in Bioseparations AFSS Annual Meeting Valley Forge, PA May 20, 2008 ABSTRACT Tom Sulpizio and Jeff Taniguchi,
More informationThe Chairperson of Korea Association for IACUC The Chairperson of SNU IACUC The Chairperson of National Animal Welfare Committee Laboratory Animal
The Chairperson of Korea Association for IACUC The Chairperson of SNU IACUC The Chairperson of National Animal Welfare Committee Laboratory Animal Medicine, College of Vet Med, SNU Prof. Jae Hak PARK 1.
More informationGuide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia
Guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins European Pharmacopoeia European Directorate for the Quality of Medicines & HealthCare Edition Council of Europe,
More informationOpportunities for Accelerating Cell Line Development and Beyond
Opportunities for Accelerating Cell Line Development and Beyond European CM&C Strategy Forum May 24, 2017 Christopher Frye, Ph.D. Research Advisor & Group Leader Bioprocess R&D Presentation Outline CM&C
More information